Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Registered for use in infants and children aged ≥6 weeks.
DTPa-hepB-IPV-Hib — diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccine
The vaccine consists of both a 0.5 mL monodose pre-filled syringe and a vial containing a lyophilised pellet.
The pre-filled syringe contains:
- ≥30 IU diphtheria toxoid
- ≥40 IU tetanus toxoid
- 25 µg pertussis toxoid
- 25 µg filamentous haemagglutinin
- 8 µg pertactin
- 10 µg recombinant hepatitis B surface antigen (HBsAg)
- 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
- 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
- 32 D-antigen units inactivated poliovirus type 3 (Saukett)
Adsorbed onto aluminium hydroxide/phosphate.
Also contains traces of:
- formaldehyde
- polysorbate 80
- polysorbate 20
- polymyxin
- neomycin
The vial containing a lyophilised pellet contains:
- 10 µg purified Hib capsular polysaccharide conjugated to 20–40 µg tetanus toxoid
May contain yeast proteins.
For Product Information and Consumer Medicine Information about Infanrix Hexa visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Allergy advice
May contain yeast proteins.